A more favourable clinical course of lymphoma relapsing after high-dose therapy: evidence of tumour heterogeneity?

Med Oncol. 2000 Aug;17(3):229-32. doi: 10.1007/BF02780534.

Abstract

Patients with Hodgkin's disease (HD) or large cell lymphomas who relapse after conventional chemotherapy have a poor prognosis without high-dose chemotherapy and stem cell transplantation (HDCT). Patients who relapse after HDCT have an extremely poor outcome. In the present study we describe four patients with relapsed HD (n=1) and large cell lymphomas (n=3) after HDCT. All had an aggressive clinical course before HDT. At relapse, however, they all have had prolonged remissions and/or spontaneous regressions on mild or no treatment. Possible explanations could be selection of less malignant clones or a lymphoma controlled by the immune system. The mechanisms are, however, unknown but warrant further studies of the molecular biology in these and similar cases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / pathology
  • Hodgkin Disease / therapy*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Remission, Spontaneous
  • Treatment Outcome